

# Whole inactivated COVID-19 vaccines: effect on adult symptomatic-COVID-19 infection

Volume 9 Issue 3 - 2022

Attapon Cheepsattayakorn,<sup>1,2</sup>  
Ruangrong Cheepsattayakorn,<sup>3</sup> Porntep  
Siriwanarangsun<sup>1</sup><sup>1</sup>Faculty of Medicine, Western University, Thailand<sup>2</sup>10th Zonal Tuberculosis and Chest Disease Center, Thailand<sup>3</sup>Department of Pathology, Chiang Mai University, Thailand

**Correspondence:** Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, 143 Sridornchai Road Changklan Muang Chiang Mai 50100 Thailand, Tel 66 53 140767; 66 53 276364, Fax 66 53 140773; 66 53 273590, Email Attapon1958@gmail.com

**Received:** September 10, 2022 | **Published:** September 14, 2022

## Editorial

Recently, a large phase-III-clinical trial on persons with age of 18 years or above, conducted by Bharat Biotech International Limited, “COVAXIN®” (BBV152), a whole virus inactivated corona virus vaccine demonstrated that two doses of its vaccine with an interval of 4 weeks of administration had 78 % of efficacy against any COVID-19 (live SARS-CoV-2) severity and 93 % of efficacy against severe COVID-19 after 14 days or more after the second dose administration.<sup>1</sup> Whereas vaccine efficacy was 79 % in adults with age of 60 years or below, and 68 % in those with age of 60 years or above.<sup>1</sup> On the median of follow-up of 99 days, the vaccine efficacy in persons with asymptomatic COVID-19 infection was 64 %.<sup>1</sup> A recent study on effect of two whole inactivated COVID-19 vaccines (two intramuscular injections, 21 days apart) among adults with symptomatic COVID-19 infection revealed that COVID-19 vaccine with 5 µg/dose (n = 13,459) and vaccine with 4 µg/dose (n = 13,465) had the vaccine efficacy of 72.8 % and 78.1 %, respectively, compared with control group (n = 13,458) of 95 % (77 days of median duration), whereas the adverse reactions at 7 days after each injection were around 41.7 % to 46.5 % of the study participants.<sup>2</sup>

In conclusion, these two whole inactivated COVID-19 vaccines could decrease the risk of symptomatic COVID-19 infection among adults, whereas the use of COVAXIN® in adults with age of 18 years or above.

## Acknowledgments

None.

## Conflict of interest

There are no conflicting interests declared by the authors.

## References

1. World Health Organization. COVID-19 Vaccine Explainer. COVID-19 vaccine (Whole virion inactivated coronavirus vaccine), BBV152, COVAXIN®. 2022.
2. Kaabi NA, Zhang Y, Xia S, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. *JAMA*. 2021;326(1):35–45.